Company
Headquarters: Beijing, China
Employees: 11,029
CN¥19.51 Billion
CNY as of July 1, 2025
US$2.72 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its subsidiaries, operates as a pharmaceutical company in the People's Republic of China. The company offers soft bag, plastic and glass bottle, inner sealed polypropylene, and polypropylene blend bag infusion products; levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, sodium chloride injection products, etc.; and peritoneal dialysate, hemodialysis dialysate, etc. It also provides compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, edaravone, and other products to treat cardiovascular and cerebrovascular diseases. In addition, the company offers products for endocrinology; and pediatric compound amino acid injection, and other drugs to treat pediatrics. Further, it provides nutritional drugs, including vitamin E and C; and anti-infective drugs. The company is headquartered in Beijing, the People's Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. is a subsidiary of Beijing Pharmaceutical Group Co., Ltd.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥11.15 B |
| EBITDA | CN¥2.09 B |
| Gross Profit TTM | CN¥6.41 B |
| Profit Margin | 14.55% |
| Operating Margin | 19.90% |
| Quarterly Revenue Growth | -2.10% |
China Resources Double-Crane Pharmaceutical Co.,Ltd. has the following listings and related stock indices.
Stock: SSE: 600062 wb_incandescent